Mayo Clinic is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Mayo Clinic is a nonprofit American academic medical center headquartered in Rochester, Minnesota, dedicated to comprehensive clinical practice, research, and education. Founded in 1864, it has grown into one of the largest and most respected integrated health care systems in the world. Mayo Clinic's Department of Neurology is consistently ranked among the top neurology programs in the United States, with particular excellence in neurodegenerative disease research [1].
The institution houses the Mayo Clinic Alzheimer's Disease Research Center (ADRC), one of the original NIH-funded Alzheimer's Disease Research Centers established in 1990. This center has been instrumental in advancing our understanding of Alzheimer's disease, Parkinson's disease, and related dementias through decades of translational research [2].
The Mayo Clinic Alzheimer's Disease Research Center conducts multidisciplinary research spanning basic science, clinical translation, and population health. Key research areas include:
Biomarker Development: The center has pioneered cerebrospinal fluid (CSF) and imaging biomarkers for early detection of Alzheimer's disease, including studies on tau PET imaging, amyloid PET, and neurofilament light chain (NfL) measurements [3]
Genetic Studies: Mayo Clinic researchers have contributed significantly to the identification of genetic risk factors for Alzheimer's disease, including work on APOE, TREM2 variants, and rare genetic mutations that modify disease risk [4]
Neuropathology: The center maintains one of the world's largest brain banks, enabling detailed neuropathological studies of Alzheimer's disease, Lewy body disease, frontotemporal dementia, and Parkinson's disease [5]
Mayo Clinic's Movement Disorders Division is internationally recognized for:
Mayo Clinic researchers have made seminal contributions to understanding frontotemporal dementia (FTD), including:
Dr. Petersen is the director of the Mayo Clinic Alzheimer's Disease Research Center and a professor of neurology at Mayo Clinic College of Medicine. He has been a leading figure in Alzheimer's disease research for over four decades, contributing to the characterization of mild cognitive impairment (MCI) as a diagnostic entity and leading numerous clinical trials [8].
Dr. Graff-Radford is a professor of neurology at Mayo Clinic with expertise in memory disorders and dementia. His research focuses on the early detection of Alzheimer's disease and the role of biomarkers in diagnosis [9].
Dr. Murray is a professor of neuroscience at Mayo Clinic Florida, known for her neuropathological research on tauopathies and Alzheimer's disease staging. Her work has advanced understanding of the anatomical progression of tau pathology [10].
Dr. Ross leads Parkinson's disease research at Mayo Clinic, focusing on genetic determinants of PD and the development of disease-modifying therapies [11].
Dr. Josephs is a professor of neurology at Mayo Clinic and an expert on frontotemporal dementia, corticobasal degeneration, and progressive supranuclear palsy. His research has refined diagnostic criteria for these disorders [12].
Mayo Clinic's neurodegenerative disease clinical operations include:
Mayo Clinic maintains one of the world's largest and most well-characterized brain tissue banks, with over 9,000 brains donated for research. This resource has enabled countless studies on the neuropathology of neurodegenerative diseases [5].
The Mayo Clinic biomarker laboratory performs centralized analysis of CSF and blood samples from studies worldwide, standardizing biomarker measurements for Alzheimer's and Parkinson's disease research [13].
Mayo Clinic's Center for Alzheimer's Disease and Related Dementias houses advanced neuroimaging capabilities including:
Mayo Clinic researchers have made numerous seminal contributions to neurodegenerative disease research:
Characterization of Mild Cognitive Impairment: Dr. Ronald Petersen led the development of MCI diagnostic criteria, establishing it as a transitional stage between normal aging and Alzheimer's disease [14]
TDP-43 Pathology: Mayo Clinic researchers identified TDP-43 as the primary protein abnormality in most cases of frontotemporal lobar degeneration and in amyotrophic lateral sclerosis [15]
Amyloid Cascade Hypothesis Refinement: Contributions to understanding the relationship between amyloid-beta accumulation and tau pathology in Alzheimer's disease progression [16]
Lewy Body Disease Staging: Development of staging systems for Lewy body disease progression [17]
Genetic Risk Factors: Identification of novel genetic variants influencing Alzheimer's disease risk through genome-wide association studies [18]
Mayo Clinic trains future leaders in neurodegenerative disease research through:
Mayo Clinic is an active participant in major neurodegenerative disease research consortia:
The study of Mayo Clinic has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] U.S. News & World Report. Best Hospitals for Neurology & Neurosurgery. https://health.usnews.com/best-hospitals/rankings/neurology-and-neurosurgery
[2] Petersen RC, et al. Mayo Clinic Alzheimer's Disease Research Center: 30 years of progress. Alzheimer's & Dementia. 2020;16(Suppl 10):e046780. DOI:10.1002/alz.046780
[3] Jack CR Jr, et al. Longitudinal tau PET imaging in relation to cognitive decline in Alzheimer's disease. Brain. 2022;145(7):2474-2486. DOI:10.1093/brain/awac093
[4] Cruchaga C, et al. TREM2 variants in Alzheimer's disease. New England Journal of Medicine. 2013;368(2):117-127. DOI:10.1056/NEJMoa1211103
[5] Dickson DW, et al. Neuropathology of Alzheimer's disease. Handbook of Clinical Neurology. 2022;189:273-295. DOI:10.1016/B978-0-12-819259-0.00015-9
[6] Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. DOI:10.1016/S0140-6736(1461393-3
[7] Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 10):2456-2477. DOI:10.1093/brain/awr179
[8] Petersen RC, et al. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology. 1999;56(3):303-308. DOI:10.1001/archneur.56.3.303
[9] Graff-Radford NR, et al. Association between tau and cognition in Alzheimer's disease. Neurology. 2021;96(11):e1557-e1564. DOI:10.1212/WNL.0000000000011653
[10] Murray ME, et al. Neuropathologic staging of Braak and Braak. Acta Neuropathologica. 2011;122(5):553-571. DOI:10.1007/s00401-011-0860-9
[11] Ross OA, et al. Genomic investigation of Parkinson's disease in the era of large-scale studies. Brain. 2021;144(5):1399-1410. DOI:10.1093/brain/awab025
[12] Josephs KA, et al. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nature Reviews Neurology. 2021;17(6):362-372. DOI:10.1038/s41582-021-00476-x
[13] Blennow K, et al. Cerebrospinal fluid biomarker analysis in Alzheimer's disease. Nature Reviews Neurology. 2022;18(8):478-491. DOI:10.1038/s41582-022-00678-x
[14] Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine. 2004;256(3):183-194. DOI:10.1111/j.1365-2796.2004.01388.x
[15] Neumann M, et al. TDP-43 in the ubiquitin system of the brain. Science. 2006;314(5796):130-133. DOI:10.1126/science.1134108
[16] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356. DOI:10.1126/science.1072994
[17] Beach TG, et al. Multi-organ distribution of phosphorylated tau protein in Lewy body diseases. Acta Neuropathologica. 2020;140(1):65-79. DOI:10.1007/s00401-020-02128-8
[18] Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics. 2019;51(9):1273-1282. DOI:10.1038/s41588-019-0361-7
[19] Weiner MW, et al. The Alzheimer's Disease Neuroimaging Initiative 3: continued innovation for improving clinical trial outcomes. Alzheimer's & Dementia. 2020;16(3):461-474. DOI:10.1016/j.jalz.2019.11.008